Cytomegalovirus Tests Market by Test Type, Sample Type, User Group, End Use

Description

List of Tables

[184 Pages Report] The Cytomegalovirus Tests Market size was estimated at USD 641.28 million in 2023 and expected to reach USD 680.78 million in 2024, at a CAGR 6.93% to reach USD 1,025.06 million by 2030.

Cytomegalovirus (CMV) tests are medical examinations used to detect the presence of the cytomegalovirus in an individual's body. The cytomegalovirus is a common virus that belongs to the herpesvirus family and can infect people of all ages. While healthy individuals often show no symptoms upon infection and may not be aware they have been infected, CMV can pose significant health risks to people with weakened immune systems and to newborns if they are infected before birth. Growing public and clinical awareness regarding the implications of CMV, especially in pregnant women and immunocompromised patients, drives the demand for CMV testing. Additionally, as the number of organ transplants increases globally, the need for precise CMV testing escalates to ensure safe and successful transplant outcomes. However, high costs and limited access to sophisticated testing facilities can impede market growth, particularly in developing regions. Moreover, complex regulatory landscapes and varying reimbursement policies across countries can create hurdles in the adoption of advanced CMV testing technologies. Furthermore, innovations in molecular diagnostics and the development of faster, more accurate testing methods contribute to market growth. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection offers the potential to improve sensitivity, specificity, and cost-effectiveness.

KEY MARKET STATISTICS
Base Year [2023]	USD 641.28 million
Estimated Year [2024]	USD 680.78 million
Forecast Year [2030]	USD 1,025.06 million
CAGR (%)	6.93%

Regional Insights

The Americas, particularly the United States and Canada, represent a significant market for cytomegalovirus (CMV) tests. Enhanced healthcare infrastructure, high healthcare spending, and an increasing awareness of the significance of early diagnosis and treatment of CMV infections contribute to the market's growth in these countries. The consumer need in the region is driven by a high standard of healthcare practices and a demand for advanced diagnostic solutions. Ongoing research and development activities, supported by both government and private sectors, aim to improve the accuracy and accessibility of CMV testing. In the European Union, the market for CMV tests is characterized by stringent regulatory standards and a vital principle on patient care and safety. EU countries benefit from a well-established healthcare system and high health awareness among the population. The consumer need within the EU is for safe, validated, and cost-effective testing options. The Middle East, with its wealthier nations like the UAE and Saudi Arabia, is witnessing a growing healthcare sector with increasing investments in healthcare infrastructure and services. Conversely, Africa faces challenges such as restricted access to healthcare facilities and an insufficiency of awareness. The APAC region is rapidly emerging as a significant CMV test market driven by increasing healthcare expenditure, economic growth, and a huge patient population. China and India, with their vast populations, have a high demand for affordable healthcare solutions, including diagnostic tests for infectious diseases such as CMV. Japan, known for its advanced healthcare system and technological innovation, demonstrates a preference for high-quality and precision diagnostics. Research and development initiatives in these countries are focused on creating cost-effective and efficient diagnostic solutions to meet local needs.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cytomegalovirus Tests Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of CMV infections across the globe
- Growing public and clinical awareness regarding the implications of CMV
- Increasing number of liver transplant globally

Market Restraints
- High cost and limited access to sophisticated testing facilities

Market Opportunities
- Innovations in molecular diagnostics and the development of faster, more accurate testing methods
- Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection

Market Challenges
- Complex regulatory landscapes and varying reimbursement policies across countries

Market Segmentation Analysis
- Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
- End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cytomegalovirus Tests Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cytomegalovirus Tests Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients

The U.S. Food and Drug Administration (FDA) has recently approved a new application for Merck's antiviral drug, Prevymis (letermovir), to include its use in preventing cytomegalovirus (CMV) disease among adult recipients of kidney transplants with high-risk. Prevymis aims to significantly reduce the risk of viral infection and associated complications by preventing the activation of the virus in patients with weakened immune systems post-transplant. This decision by the FDA was supported by robust clinical trials that demonstrated the drug's effectiveness and safety in this new patient demographic, paving the way for its broader use in transplant medicine. [Published On: 2023-06-06]

DiaSorin's Breakthrough in Congenital CMV Detection

DiaSorin, an Italian diagnostic firm, announced its achievement in gaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative Simplexa Congenital CMV Direct kit. This cutting-edge diagnostic tool marks a significant milestone as the first FDA-approved test to detect cytomegalovirus (CMV) DNA in both saliva and urine samples of newborns aged 21 days or younger. Integrating this test into the Liaison MDx instrument facilitates swift and accurate diagnoses of congenital CMV, enabling timely interventions and treatments. [Published On: 2022-11-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cytomegalovirus Tests Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cytomegalovirus Tests Market, highlighting leading vendors and their innovative profiles. These include Abbexa Ltd., Abbott Laboratories, Accubiotech Co., Ltd, AdvaCare Pharma USA, Agilent Technologies, Inc., Atlas Medical GmbH, Bio-Rad Laboratories, Inc., Biogenix Inc. Pvt. Ltd., CLONIT srl, Creative Diagnostics, CTK Biotech Inc. by SSI Diagnostica A/S, Diasorin S.p.A., Elabscience Bionovation Inc., F. Hoffmann-La Roche Ltd., Hangzhou Realy Tech Co., Ltd., Intec Products, Inc., IQ Products B.V., Jiangsu Macro & Micro-Test Med-Tech Co., Ltd., Meridian Bioscience, Inc. by SD Biosensor, and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

Test Type
- Antigenemia Tests
- Culture Tests
- Molecular Tests
- Serological Tests

Sample Type
- Blood Samples
- Urine Samples

User Group
- Immunocompromised Individuals
- Newborns
- Pregnant Women

End Use
- Diagnostic Laboratories
- Hospitals & Clinics
- Research Institutions

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-6B0EA07975A5

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of CMV infections across the globe
  - 5.1.1.2. Growing public and clinical awareness regarding the implications of CMV
  - 5.1.1.3. Increasing number of liver transplant globally
- 5.1.2. Restraints
  - 5.1.2.1. High cost and limited access to sophisticated testing facilities
- 5.1.3. Opportunities
  - 5.1.3.1. Innovations in molecular diagnostics and the development of faster, more accurate testing methods
  - 5.1.3.2. Leveraging next-generation sequencing and CRISPR-based technologies for CMV detection
- 5.1.4. Challenges
  - 5.1.4.1. Complex regulatory landscapes and varying reimbursement policies across countries
5.2. Market Segmentation Analysis
- 5.2.1. Test Type: Ongoing advancements in molecular tests especially particularly polymerase chain reaction to improve sensitivity and specificity
- 5.2.2. End Use: Increasing utilizations of cytomegalovirus tests by research institutions for vaccine development
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Cytomegalovirus Tests Market, by Test Type

6.1. Introduction
6.2. Antigenemia Tests
6.3. Culture Tests
6.4. Molecular Tests
6.5. Serological Tests

7. Cytomegalovirus Tests Market, by Sample Type

7.1. Introduction
7.2. Blood Samples
7.3. Urine Samples

8. Cytomegalovirus Tests Market, by User Group

8.1. Introduction
8.2. Immunocompromised Individuals
8.3. Newborns
8.4. Pregnant Women

9. Cytomegalovirus Tests Market, by End Use

9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Institutions

10. Americas Cytomegalovirus Tests Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cytomegalovirus Tests Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cytomegalovirus Tests Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Approves Expanded Use of PREVYMIS by Merck to Prevent CMV in High-Risk Kidney Transplant Recipients
- 13.3.2. DiaSorin's Breakthrough in Congenital CMV Detection
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio